Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, randomized, double-blind, placebo-controlled,
parallel-group, large simple trial to investigate the efficacy and safety of a single
intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or
suspected acute major bleeding and / or predicted to receive a large volume blood product
transfusion.